Lombardi Comprehensive Cancer Center

Washington D.C., District of Columbia 22057

2 studies enrolling now · 18 studies all time

What they study most

Acral Lentiginous Melanoma, Advanced Solid Tumors, Breast Cancer, Colorectal Adenocarcinoma, Colorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumors, GI Cancer, Glioblastoma, IDH-wildtype, Hemophilia A With Inhibitor, Hemophilia B With Inhibitor

Studies at this site

• Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer — Recruiting now
• Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma — Paused
• PRospective Multiple Myeloma Impact Study — Running, not enrolling
• LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy — Completed
• Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma — Running, not enrolling
• A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma — Paused
• Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter — Stopped early
• WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor — Completed
• A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab — Stopped early
• Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma — Stopped early
• Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies — Stopped early
• Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients — Completed
• A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia — Enrolling by invitation
• CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) — Status unconfirmed
• Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 — Stopped early
• Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B — Stopped early
• A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1) — Stopped early
• PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen — Status unconfirmed